观察异甘草酸镁预防布鲁菌病肝损害的临床价值。

214例布鲁菌病患者被随机分为观察组110例、对照组104例。对照组患者常规给予多西环素、利福霉素联合抗布鲁杆菌治疗，观察组患者在对照组的基础上，加用异甘草酸镁150 mg/d、1次/d静脉滴注，2周后改甘草酸二胺150 mg口服，共6周。

对照组和观察组患者的转氨酶异常率为36.5%和14.6%，差异具有统计学意义（χ²= 13.70、P = 0.000），发生于入院2周后转氨酶异常率分别占29.8%和12.7%（χ²= 9.39、P = 0.002），差异具有统计学意义；入院4～6周后转氨酶异常率占6.7%和1.8%（χ²= 3.20、P = 0.74），差异无统计学意义。肝功能损害程度，对照组和观察组的丙氨酸氨基转移酶（ALT）为（153.3±76.9）U/L和（78.1±34.3）U/L（t = 2.28、P = 0.016），天门冬氨酸氨基转移酶（AST）为（127.5±62.1）U/L和（62.2±31.8）U/L（t = 2.03、P = 0.039），差异均具有统计学意义。对照组和观察组患者利福霉素停药率分别为30.8%和10.9%（χ²=12.91、P = 0.000）。

异甘草酸镁对预防布鲁菌病肝损害具有较好的临床价值。

To investigate the clinical value of magnesium isoglycyrrhizinate (MIG) in prevention of liver damage caused by Brucellosis.

Total of 214 cases with Brucellosis were randomly divided into the observation group (110 cases) and control group (104 cases). The patients in control group were given conventional combined anti-Brinellcoli treatment with doxycycline and rifamycin. The patients in observation group were added 150 mg/d MIG once a day on the base treatment of the control group, and changed into oral glycyrrhizic acid diamine 150 mg after 2 weeks, all for totally 6 weeks.

The aminotransferase abnormality rate were 36.5% and 14.6% (χ² = 13.70, P = 0.000), 29.8% and 12.7% (χ² = 9.39, P = 0.002) after 2 weeks treatment and 6.7% and 1.8% (χ² = 3.20, P = 0.74) after 4-6 weeks treatment for the patients in control group and the observation group, respectively. For the degree of liver damage, ALT were (153.3±76.9) U/L and (78.1±34.3) U/L (t = 2.28, P = 0.016), AST were (127.5±62.1) U/L and (62.2±31.8) U/L (t = 2.16, P = 0.024) for the patients in control group and the observation group, all with significant difference. The rate of rifamycin withdrawal were 30.8% and 10.9% (χ² = 12.91, P = 0.000) for the control group and the observation group, respectively.

MIG had a reliable clinical value in the prevention of the damage caused by Brucellosi.